Study Funding List - Alliance - Home



Cancer Control Program

Cancer in the Elderly Committee

200 First Street, SW

Rochester, MN 55905

P: 507-266-9202

F: 507-284-1803



Harvey J. Cohen, M.D.

Hyman B. Muss, M.D.

Co-Chairs

Agenda

Cancer in the Elderly Committee Meeting

Saturday, November 9, 2013

8:00-10:00 AM CST

Guggenheim 3

Meeting available by teleconference: Dial 800-501-8979 Access Code: 1165588

Meeting available by webconference: log into conferencing, click on the "Join a Conference" option, enter 8005018979 followed by the 7-digit access code: 1165588. You will be asked to enter your name, email, phone and company. Only the name is required.

|Committee Leadership: |Role |E-mail |

|Harvey J. Cohen, MD |Co-Chair |Harvey.cohen@duke.edu |

|Hyman B. Muss, MD |Co-Chair |muss@med.unc.edu |

|Arti Hurria, MD |Co-Vice Chair |ahurria@ |

|Aminah Jatoi, MD |Co-Vice Chair |jatoi.aminah@mayo.edu |

|Karla V. Ballman, PhD |Statistician |ballman.karla@mayo.edu |

|Jacob Allred, MS |Statistician |allred@mayo.edu |

|Brandy Pitcher, MS |Statistician |brandy.pitcher@duke.edu |

|Jackie Lafky, MS |CCP Program Manager |Lafky.jacqueline@mayo.edu |

I. Scientific Presentations (10 minutes presentation/5 minutes Q&A each)

A. Geriatric Assessment for Allogeneic Transplant In Older Adults (Andy Artz, MD)

B. Improving Outcomes of Older Patients with Cancer using Geriatric Assessment (Supriya Mohile, MD, MS)

C. Biomarker, Imaging & QOL Studies Funding Program: Changes and Opportunities (Ray Petryshyn, PhD)

D. A081203: A Phase II Randomized Trial of Utilizing Geriatric in treatment allocation of patients >70 years with Advanced Non-Small Cell Lung Cancer (Ajeet Gajra, MD)

E. Findings from the Institute of Medicine (IOM) report “Committee on Improving the Quality of Cancer Care: Addressing the Challenges of an Aging Population (Arti Hurria, MD)

II. Study Updates – Around the Room (45 minutes)

A. Previously Presented Concepts

1. Joleen Hubbard, MD: Biomarkers of Frailty Among Patients with Colorectal Cancer

2. John Grecula, MD: Phase I Evaluation of Minocycline As a Neuroprotector in Older Adult Patients Receiving Prophylactic Cranial Radiotherapy for Small Cell Lung Carcinoma

3. Jennifer Woyach, MD: (A041202) A Randomized Phase III Study of Chlorambucil Plus Rituximab Versus Ibrutinib Plus Rituximab Versus Ibrutinib Alone In Untreated Older Patients With Chronic Lymphocytic Leukemia (CLL)

4. Rachel Freedman, MD: (RU011301I) Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

5. Aminah Jatoi, MD and Waddah Al-Refaie, MD: A Weekly Phone-based Intervention to Improve Outcomes in Elderly (>70 Years Old), Postoperative Pancreas Cancer Patients

B. Data Mining Updates

1. Jeanne Mandelblatt, MD: (361001) Comparing Receipt of Chemotherapy within a Clinical Trial vs. Routine Practice: Predictors and Outcomes among Older Breast Cancer Patients

2. Rachel Freedman, MD: (361002) Changes in cognitive function in elderly women treated with standard chemotherapy and capecitabine within CALGB 49907

3. Heidi Klepin, MD: (361004) Associations between comorbidity, chemotherapy toxicity, and clinical outcomes among older women receiving adjuvant therapy for breast cancer in CALGB 49907

4. Arti Hurria, MD: (361007) Changes in Functional Status Among Older Adults who Receive Adjuvant Chemotherapy for Breast Cancer (Retrospective Analysis using 49907 data)

5. Jeanne Mandelblatt: (369901) Observational cohort study: Chemotherapy decisions and outcomes in women age 65 or older with operable, newly diagnosed breast cancer

6. Stu Lichtman, MD: (A171201) Ancillary Data Study of 49907: Standard Chemotherapy (CMF or AC) versus Capecitabine in Early-Stage Breast Cancer (BC) Patients Aged 65 and older: Results of CALGB/CTSU 49907

7. Aminah Jatoi, MD: (A171301) Exploring Associations Between Social Support and Clinical Outcomes in Elderly Patients Enrolled in CALGB 49907

8. Judy Hopkins, MD: (A171302) Musculoskeletal Events in Elderly Patients Receiving Adjuvant Chemotherapy for Breast Cancer

9. Ajeet Gajra, MD: 49907 Correlative - Association of Baseline Patient Attitudes Towards Chemotherapy Benefit and Self Health with QoL, Toxicity, Mental Health and Function in Women Treated on CALGB 49907

10. Myra Barginear, MD: Chemotherapy-induced Neuropathy of All Grades in a Group of Elderly Patients

11. Gretchen Kimmick, MD: Estimate of Survival and Validating Using the Online Prognosis Estimation from Eprognosis

C. Open Studies – Updates

1. Michael Jaklitsch, MD: 140801 - Geriatric assessment for older patients considering thoracic surgery

D. Closed Studies – Publications Pending; Provided as an FYI only

1. Heidi Klepin, MD:(361006) Geriatric Assessment in CALGB 11001: Ph II Study Incorporating Sorafenib (IND 69896, NSC 724772) into the Therapy of Pts e 60 Years of Age with FLT3 Mutated Acute Myeloid Leukemia

2. Heidi Klepin, MD: (361101) Geriatric Assessment in CALGB 11002: Randomized Ph II Trial of Decitabine-based Induction Strategies for Pts e 60 Years Old w/AML

3. William Cance, MD: (159805) Laboratory Studies in Elderly Women with Breast Cancer: Companion to CALGB 9343

4. (40502) A randomized phase III trial of weekly paclitaxel compared to weekly nanoparticle albumin bound NAB - paclitaxel or ixabepilone with or without bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer

5. Maura Dickler, MD: (40503) Endocrine therapy with or without anti-VEGF therapy: A randomized, phase III trial of endocrine therapy alone or endocrine therapy plus bevacizumab (NSC 704865: IND 7921) for women with hormone receptor-positive advanced breast cancer

6. Elizabeth Lamont, MD: (70802) Population-based assessment of cancer trial generalizability in the elderly

7. Thomas Habermann, MD: (9793) A phase III trial of CHOP versus CHOP and chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in older patients with diffuse mixed, diffuse large cell and immunoblastic large cell histology non-Hodgkin's lymphoma

8. Aminah Jatoi, MD: (N0747) A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (with the potential for crossover) for Elderly and/or Poor Performance Status Patients with Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction

9. Grace Dy, MD: (N0821) A phase II first-line study of a combination of pemetrexed, carboplatin and bevacizumab in advanced nonsquamous NSCLC evaluating efficacy and tolerability in elderly patients (age >/=70 yrs) with good performance status (PS ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download